Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? What do experts say? September 23, 2019.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. 30 May 2019.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

CannaTech

JANUARY 16, 2019

Pharmaceutical grade cannabis is relatively new in parts of the world. This statistic accounts for medicines treating patients with epilepsy, anxiety, depression, chronic pain, and other illnesses. Legal access does not necessarily equate to financial access. million people.

Access 89

Access Patients Pharmaceutical Education 89

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Accessed July 25, 2021. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Veriheal

JULY 26, 2023

Georgia medical cannabis patients will soon have greater access to treatment as cannabis oil will be sold in many more pharmacies. Eligible patients were granted access to low-THC marijuana oil. Andrew Turnage, the executive director of the Georgia Access to Medical Cannabis Commission, spoke on this fact.

Oil 98

Oil Patients Access THC 98

Cannabis Law Report

DECEMBER 11, 2021

. 'A monumental shame' @AndyMcDonaldMP continuing to highlight how families continue to be passed from pillar to post as the Government fail to continue to tackle the necessary barriers to widen access to life-saving #medicalcannabis prescriptions. He recounted his experience of losing his son to epilepsy. “I Read more at.

Treatment 52

Treatment Access Patients Medicine 52

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. The industry also encourages the development of novel pharmaceuticals and treatments, creating opportunities for Maryland residents to access cutting-edge healthcare options.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

JULY 6, 2021

It appears most likely to be used for small children with severe myoclonic epilepsy, known as Dravet syndrome. According to the Epilepsy Foundation, Dravet syndome is rare, drug-resistant and leads to prolonged seizures. He said the department had a pharmaceutical products tendering process every two years.

Medicine 105

Medicine Epilepsy Pharmaceutical Access 105

MMJ Recs

NOVEMBER 20, 2023

Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. For example, the discovery of CBD’s effectiveness in managing epilepsy led to the development of Epidiolex, the first FDA-approved medication derived from marijuana.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

MMJ Recs

APRIL 1, 2024

Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment. Its non-addictive nature and minimal side effects make it an attractive alternative to conventional pharmaceuticals for many individuals seeking natural remedies.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JULY 24, 2019

But it is important that access to it is delivered in a way that fits in with other treatment options. It has been widely reported in the media that parents with children suffering from intractable epilepsy continue to experience difficulties in securing prescriptions for medical cannabis products containing THC.

Epilepsy 40

Epilepsy Medicine Treatment Patients 40

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

LifeCannMD

NOVEMBER 24, 2023

Medical marijuana may be recommended for conditions such as chronic pain, epilepsy, multiple sclerosis, Crohn’s disease, cancer, and other qualifying conditions. Patients love that it is from mother nature and is a less addictive alternative to pharmaceutical drugs with major side effects.

Marijuana 52

Marijuana Chronic Pain Conditions Patients 52

SpeedWeed

AUGUST 9, 2021

Argentinian health authorities are now providing access to cannabis derivatives for medicinal, therapeutic and palliative purposes. The first supply of medical cannabis for pediatric patients with epilepsy at the Buenos Aires National Children’s Garrahan Hospital was finally delivered. Shutterstock. It modified Law No.

Epilepsy 52

Epilepsy Research and Development Medicine Patients 52

Veriheal

SEPTEMBER 27, 2021

The United Kingdom’s Multiple Sclerosis (MS) Society has taken a stand against restricted access to medical cannabis in the country. Medical cannabis has been legal in the nation for almost three years—so why are MS patients struggling to access the treatment? Yet many people with MS are still unable to access it.”

Treatment 98

Treatment Patients Access Research and Development 98

The Cannigma

JUNE 25, 2022

Patients must have a doctor’s prescription as well as permission from a regional pharmaceutical inspector to obtain cannabis products. Qualifying conditions include chronic pain, multiple sclerosis, spasticity, chemo-induced nausea, and treatment-resistant epilepsy. These products are typically more accessible in larger cities.

Legalization 112

Legalization Supply Chain Chronic Pain Tincture 112

The Cannigma

JUNE 1, 2021

Patients can take part if they have a medical condition which has not responded to pharmaceutical drugs. Some of the qualifying health conditions include epilepsy, neuropathic pain, chemotherapy side effects, a need for palliative care, and pain linked to multiple sclerosis, according to France24.

Law 115

Law Epilepsy Programs Patients 115

Cannabis Law Report

FEBRUARY 1, 2022

Medical cannabis and psychedelics are being increasingly recognised by health professionals for their superior safety and efficacy compared to conventional pharmaceuticals. Due to its illegality and stigma, patients greatly suffered from an inability to access this medicine.

Pharmaceutical 52

Pharmaceutical Medicine Safety Epilepsy 52

CannaTech

AUGUST 9, 2018

We are delighted to introduce you to some new friends set to make a big impact on the medical cannabis advocacy scene… the creators of a new documentary called Separating the Strains ; a deeply personal narrative that charts the reality of living with epilepsy, with and without cannabis medication as a treatment option.

Strains 69

Strains Epilepsy Advocacy Medicine 69

Cannabis Law Report

DECEMBER 18, 2019

…MGC Pharmaceuticals has achieved yet another significant milestone with the bio-pharma company this week surpassing more than 1,800 prescribed products of its medicinal cannabis-based pharmaceutical products in Australia, UK, Brazil and Ireland. The West Australian reports. Source: [link].

Research and Development 59

Research and Development Clinical Trials Seed-To-Sale Pharmaceutical 59

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

MMJ Recs

MAY 15, 2022

This initial MMJ legislation only allowed patients suffering from intractable epilepsy to use cannabis oil. But in the years since 2017, lawmakers have steadily improved Virginia’s medical marijuana program and made it accessible to a wider range of people. Recently, Virginia legalization has changed in several ways.

Patients 52

Patients Marijuana Pharmaceutical Dispensary 52

Veriheal

AUGUST 9, 2023

CBD, Trema micrantha, and the Study’s Significance CBD means cannabidiol , one of over a hundred compounds in the cannabis plant, and is widely celebrated as a potential treatment for a long list of health concerns, including chronic pain , epilepsy , i nsomnia , anxiety , and skin allergy.

CBD 96

CBD Cannabinoids THC Extraction 96

MMJ Recs

FEBRUARY 3, 2024

Pennsylvania Medical Cannabis Program and Philadelphia Marijuana Dispensaries The Pennsylvania Medical Cannabis Program serves as the foundation for medical marijuana accessibility in Philadelphia. This can lead to a decreased reliance on pharmaceuticals that may adversely affect patients’ health and overall lifestyle.

Legislation 52

Legislation Law Marijuana Dispensary 52

WeedAdvisor

SEPTEMBER 26, 2019

Created for the treatment of two severe childhood epilepsy disorders – Lennox Gastaut Syndrome (LGS) and Dravet Syndrome – the drug recently received approval for use in the European Union. Considering that a year’s worth of Epidiolex costs over $32,000 USD, GW Pharmaceuticals will see record profits from its new invention.

CBD 40

CBD Pharmaceutical Research and Development Epilepsy 40

Cannabis Law Report

MARCH 25, 2020

Panaxia’s CBD-rich oil is targeted at specific group of patients that require a miniscule dose of THC (categories C20, C24) among whom is a large group of children suffering from epilepsy or autism spectrum disorder (ASD). About Panaxia Israel. Panaxia was founded by Dr. Dadi Segal , Dr. Eran Goldberg and Assi Rotbart , LL.b,

Oil 45

Oil Pharmaceutical Epilepsy Extraction 45

Cannabis Law Report

DECEMBER 22, 2019

Cannabis-based medicine is to be fast-tracked into the NHS , allowing thousands of people to be prescribed the drugs, including children with severe epilepsy. Living with or caring for someone with severe epilepsy is exceptionally challenging, especially as there are so few treatments available for the rare forms of the condition.

Epilepsy 59

Epilepsy Medicine Treatment Pharmaceutical 59

SpeedWeed

AUGUST 9, 2021

It’s an issue around the world: Governments continue to approve expensive, cannabis-based pharmaceutical products for medicinal use, while cultivation of the plant remains illegal for patients (and their families) to grow at home. Thankfully, Peru recently corrected this problem by passing a law in July that expands cannabis patients’ rights.

Law 52

Law Legalization Hydroponic Medicine 52

Cannabis Law Report

JUNE 7, 2019

The farm is run by GW Pharmaceuticals, where around two million cannabis plants have been produced since its opening in 1998. Those suffering from epilepsy, nausea and chronic pain due to chemotherapy are now given the option to get the drug on prescription, reports The Mirror . Something has finally happened in Sittingbourne.

Chronic Pain 40

Chronic Pain Epilepsy Legalization Pharmaceutical 40

Veriheal

MAY 17, 2021

Other states have gone beyond just medical access and have also legalized retail cannabis markets for adult consumers. Please don’t further the lie by voting for any form of legalization beyond the pharmaceutical remedies already available under state law.” ” State Doctors Oppose Legalization in Alabama.

Legalization 93

Legalization Pharmaceutical Therapy Chronic Pain 93

Cannabis Law Report

DECEMBER 1, 2019

A young girl with a drug-resistant form of epilepsy is believed to be the first and only patient in Singapore who has been given approval to use cannabis-derived medication. The move follows approvals by lawmakers in the United States to use the medication to treat rare kinds of childhood epilepsy in that country.

Epilepsy 59

Epilepsy Cannabinoids Therapy Treatment 59

Cannabis Law Report

NOVEMBER 23, 2021

The products to be manufactured at the facility aren’t specified, but will be used for managing chronic pain, epilepsy, multiple sclerosis, and pain associated with palliative care. The subject land is zoned RU1 Primary Production. Further information on the proposed project can be found here.

Chronic Pain 52

Chronic Pain Epilepsy Environment Pharmaceutical 52